A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
The CYPRESS-1 trial evaluated the combination of pegilodecakin (AM0010) with pembrolizumab in patients with advanced wild type non-small cell lung cancer (NSCLC) exhibiting high PD-L1 expression. Despite the potential for enhanced efficacy through combination therapy, the trial was terminated early due to an unfavorable risk-benefit ratio. This raises concerns regarding the commercial viability of pegilodecakin in this indication, particularly in a competitive landscape dominated by established therapies such as pembrolizumab alone. The early termination may impact Eli Lilly's strategic positioning and investment in immuno-oncology, necessitating a reassessment of their pipeline and potential partnerships.
Indication: Non Small Cell Lung Cancer
Modality: protein therapy
Target: PD-1/PD-L1 pathway modulation
Sponsor: Eli Lilly and Company
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: PD-1/PD-L1 pathway modulation
View original source fields
Condition raw: Non Small Cell Lung Cancer
Condition normalized: Non Small Cell Lung Cancer
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: PD-1/PD-L1 pathway modulation
Target normalized: PD-1/PD-L1 pathway modulation